Thursday, March 8, 2018

Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

Markets Insider-2 hours ago
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is dedicated to making high quality innovative medications accessible and affordable in all 50 states. The company's flexible business model allows a drug to be compounded or developed as an FDA-approved product through one of its subsidiaries or spin-out companies.
Imprimis reports 4Q loss
Olean Times Herald-18 hours ago
Post a Comment